Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GBMA Set For New Australian Pact

Welcomes ‘Pandemic Budget’ And Praises Government COVID Response

Executive Summary

Australian off-patent industry association the GBMA says it has begun negotiations on a new strategic agreement with the government that will offer “long-term certainty” for the sector. Meanwhile, the industry body has praised the latest “pandemic budget” measures to address the impact of COVID-19.

You may also be interested in...



Fresh Australian Industry Pact Will Insure Against Shortages

A fresh five-year strategic agreement struck between Australian off-patent industry association the GBMA and the country’s government offers sustainability and stability for Australia’s generics sector, with the body committing to holding safety stocks of certain drugs within the country to protect against potential shortages in the context of the COVID-19 pandemic.

Lupin Acquires Australia’s Southern Cross

Lupin has broadened its reach in Australia after agreeing a deal to buy local generics developer and distributor Southern Cross.

Who’s Hired? AAM Makes Three Key Appointments

The US Association for Accessible Medicines hires for three key leadership roles, while Australia’s Generic and Biosimilar Medicines Association has named Fresenius Kabi’s director in Australia as its newest board member. Coherus’ vice president of market access and government affairs, Thomas Nusbickel, joins CorMedix as chief commercial officer, while other major firms make board changes.

Related Content

Topics

UsernamePublicRestriction

Register

GB150324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel